Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629 1649 1674 1675 1678
This examiner grants 60% of resolved cases
Laura Ann Essex is an examiner in Tech Center 1600 and Art Unit 1629 with 114 resolved cases. The allowance rate of 60.5 percent indicates a moderate success rate for applicants, showing that while grants are common, the examination process remains thorough. However, the median days to allowance is 1310, showing that the process can be quite lengthy and requires a long-term commitment from the applicant.
The data shows a significant interview lift of 35.2 percent. This high lift suggests that interviews are an extremely effective strategy for moving cases toward allowance, potentially overcoming the challenges that lead to the 60.5 percent baseline. With 114 resolved cases, the 35.2 percent lift is a strong signal that direct communication can help mitigate the 1310-day wait for an allowance. Practitioners should prioritize interviews to take advantage of this 35.2 percent increase in the probability of a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18468633 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | Final Rejection | The Regents of the University of California |
| 18045981 | Thermoresponsive or Shear-Thinning Injectable Gel Compositions for Treatment of Arthritis | Non-Final OA | GLOBUS MEDICAL, INC. |
| 18531856 | GITR ANTAGONISTS AND METHODS OF USING THE SAME | Non-Final OA | Eli Lilly and Company |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 16825181 | MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE | Non-Final OA | Roche Diagnostics Operations, Inc. |
| 18336282 | LABELED POLYPEPTIDE, MODIFIED POLYPEPTIDE, PRODUCTION METHOD FOR THESE POLYPEPTIDES, REAGENT CONTAINING THESE POLYPEPTIDES, AND MEASUREMENT METHOD FOR TARGET SUBSTANCE | Non-Final OA | SYSMEX CORPORATION |
| 17600957 | METHODS OF PREDICTING AND PREVENTING CANCER IN PATIENTS HAVING PREMALIGNANT LESIONS | Non-Final OA | Trustees of Boston University |
| 18339960 | METHODS FOR TREATING MULTIPLE SCLEROSIS WITH OCRELIZUMAB | Non-Final OA | Hoffmann-La Roche Inc. |
| 18008798 | Camptothecin Drug Having High-Stability Hydrophilic Connecting Unit And Conjugate Thereof | Non-Final OA | SICHUAN BAILI PHARM CO., LTD |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy